AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $243.90
- 52-wk high
- $258.30
- High
- $245.83
- 52-wk low
- $144.37
- Low
- $239.43
- Prev close
- $247.18
- Mkt cap
- $55.82B
- P/E
- 33.1x
- Volume
- 1.60M
- Fwd P/E
- 19.1x
- Beta
- 0.52
- Div yield
- 0.85%
- P/S
- 0.2x
- P/B
- 16.1x
- Profit margin
- +0.7%
- Op margin
- +1.3%
- ROE
- +0.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 20.2% above what analysts expected.
Earnings per share
$2.42 expected
Revenue
$65.11B expected
GAAP EPS was $1.70 and adjusted EPS was $2.91. The analyst basis could not be confirmed, so no beat or miss is shown.
Reports Oct 29, 2026, in 49 days
EPS expected
$2.88 to $3.06
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $64.01B | $65.44B | $60.94B | $63.86B |
| Cost of what it sold | $61.69B | $63.23B | $58.44B | $61.11B |
| Gross profit | $2.32B | $2.21B | $2.50B | $2.75B |
| What it spent | ||||
| Sales and admin | $1.46B | $1.50B | $1.54B | $1.63B |
| Other operating costs | $190.0M | — | $447.0M | $392.0M |
| Total operating expenses | $1.65B | $1.50B | $1.99B | $2.02B |
| What was left | ||||
| Operating profit | $668.0M | $707.0M | $509.0M | $729.0M |
| Interest on debt | $80.0M | $88.0M | $101.0M | $79.0M |
| Profit before tax | $598.0M | $630.0M | $392.0M | $554.0M |
| Tax | $144.0M | $159.0M | $12.0M | $154.0M |
| Net profit | $450.0M | $471.0M | $399.0M | $394.0M |
| EBITDA | $911.0M | $707.0M | $741.0M | $1.12B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Under the Radar: 3 Small-Cap Dividend Growers Built to Compound
Leans bullishSep 8McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
NeutralSep 8McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
NeutralSep 6AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
NeutralSep 5AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
NeutralSep 4Cencora (COR) Unveils Cell And Gene Therapy Enablement Service
NeutralSep 4Jim Cramer Makes Bold Cardinal Health (NYSE: CAH) Claim As Specialty Push Drives Earnings Growth
BullishSep 4Cardinal Health leases Sacramento building for 100-job distribution center
Leans bullishSep 4
Macro
10 macro signals shaping CAH right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results